Novan (NASDAQ:NOVN)‘s stock had its “buy” rating restated by analysts at Cantor Fitzgerald in a report issued on Tuesday, Analyst Price Targets reports.
NASDAQ NOVN opened at $8.43 on Tuesday. The stock’s fifty day moving average is $8.76 and its two-hundred day moving average is $6.10. The firm has a market capitalization of $158.59 million, a P/E ratio of -3.68 and a beta of -0.02. Novan has a fifty-two week low of $4.33 and a fifty-two week high of $25.90.
Novan (NASDAQ:NOVN) last released its quarterly earnings data on Thursday, August 12th. The company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.14. The company had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.84 million. Novan had a negative return on equity of 274.05% and a negative net margin of 759.49%. On average, equities research analysts predict that Novan will post -1.84 earnings per share for the current fiscal year.
Novan Company Profile
Novan, Inc is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline include SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.
Featured Article: The risks of owning bonds
Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with MarketBeat.com's FREE daily email newsletter.